Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 522Neoplasms 470Carcinoma, Non-Small-Cell Lung 393Prostatic Neoplasms 302Colorectal Neoplasms 296Lung Neoplasms 259Neoplasm Metastasis 217Ovarian Neoplasms 198Leukemia, Myeloid, Acute 194Pancreatic Neoplasms 185Multiple Myeloma 172Squamous Cell Carcinoma of Head and Neck 133Recurrence 132Stomach Neoplasms 129Brain Neoplasms 126Melanoma 123Carcinoma, Hepatocellular 123Endometrial Neoplasms 120Glioblastoma 118Triple Negative Breast Neoplasms 111Precursor Cell Lymphoblastic Leukemia-Lymphoma 105Hematologic Neoplasms 99Head and Neck Neoplasms 97Carcinoma, Renal Cell 96Lymphoma 93Urinary Bladder Neoplasms 90Sarcoma 90Glioma 88Lymphoma, Large B-Cell, Diffuse 81Small Cell Lung Carcinoma 80

Interventions

exemestane 1Fulvestrant 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Unilateral Breast Neoplasms × 90 days × Clear all
NCT07187726 2026-05-19

PRE-ACT-01

UNICANCER

Phase NA Recruiting
724 enrolled
Breast

Unilateral Breast Neoplasms

NCT07062965 2026-05-06

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Pfizer

Phase 3 Recruiting
400 enrolled
Breast

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡